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Abstract 
Our increasing understanding of the molecular pathogenesis of non-small cell lung 
cancer (NSCLC), particularly adenocarcinomas, has opened the door to ‘personalised 
medicine’ and the advent of new therapeutic strategies. Over the last few years new 
drugs, or classes of drugs, have been licensed and entered clinical practice for use in 
advanced NSCLC. The activity of these drugs is dependent on the presence of specific 
molecular or protein changes in cancer cells which are usually identified using 
‘companion diagnostic tests’ specifically designed for this purpose. Pathologists and 
Pathology Departments have had to forge new links with Clinical Scientists in order to 
facilitate these additional investigations on the, often limited, tissue obtained for 
diagnosis. This collaboration plays a critical role in providing the link that allows 
integration of the traditional morphological diagnosis with the results of these new 
‘companion diagnostic’ tests to guide patient management. 
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Introduction 
Lung cancer is the leading cause of cancer-related death worldwide and, despite 
significant advances in public health policy, delineation of disease pathogenesis and 
novel therapeutic strategies, mortality rates remains dismal.  Historically, 
histopathological classification has divided tumours into two separate categories, 
small cell and non-small cell lung carcinoma (SCLC, NSCLC respectively) with the 
latter accounting for approximately 80% of all malignant primary lung tumours.  Further 
morphological and immunohistochemical subclassification divides NSCLC into several 
entities of which the most common are adenocarcinoma, squamous cell carcinoma 
and large cell carcinoma.  Previously, the distinction in tumour type beyond NSCLC 
had little influence on clinical management as chemotherapeutic agents and regimens 
were limited.  Improved understanding of the underlying disease mechanisms and 
somatic driver mutations has, however, highlighted the need for detailed, definitive 
phenotypic and genotypic characterisation to establish the correct diagnosis, inform 
prognosis and guide therapeutic decisions.  The advent of personalised medicine in 
lung cancer management and the central place of the histopathologist in this process 
serves as a paradigm for the future role of pathology within the multidisciplinary teams 
throughout all cancer fields. 
 
Molecular Pathogenesis in NSCLC 
The development of NSCLC occurs due to numerous distinct somatic mutations 
occurring in a heterogeneous population of tumour progenitor cells.  Adenocarcinomas 
typically arise from epithelial cells in the terminal respiratory unit and display variable 
morphological appearances including acinar, lepidic and papillary patterns commonly 
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expressing thyroid transcription factor 1 (TTF1) and cytokeratin 7.  Squamous cell 
carcinomas are characteristically more central lesions arising from basal bronchial 
epithelial cells and often arise in the context of squamous metaplasia.  Morphologically 
these lesions typically demonstrate keratinisation and intercellular bridge formation 
with concomitant p40 and p63 expression.  Whilst most lung cancers are associated 
with tobacco smoke and other inhaled carcinogens there is a group of “never-smokers” 
who develop adenocarcinomas which often have a distinct molecular phenotype (1).   
 
The advent of next generation sequencing (NGS) and other high throughput modalities 
has highlighted the complex interplay of genetic and epigenetic factors as well as the 
tumour microenvironment in determining tumour development.  This has lead to the 
identification of ‘early driver mutations’ in key oncogenes which are believed to be 
important in tumour development and growth. Oncogenes associated with 
adenocarcinoma include activating mutations in the epidermal growth factor receptor 
(EGFR) gene and translocations of the anaplastic lymphoma kinase (ALK) and ROS1 
gene as well as KRAS, hepatocyte growth factor receptor (MET), RET and human 
epidermal growth factor receptor 2 (HER2) mutations (2).  Interestingly 
adenocarcinomas in ‘non-smokers’ show a significantly higher frequency of mutations 
in EGFR, ALK and ROS while smokers show a high frequency of KRAS mutations 
suggesting potentially different pathogenetic mechanisms of tumour development in 
smokers and non-smokers (1). The frequency of these abnormalities is, however, also 
influenced by geographic / ethnic factors with EGFR and ALK driver abnormalities 
seen in 10-15% of white European patients but 60% of those of Asian origin (1,3).  
Somatic driver mutations in squamous cell carcinoma include discoidin domain-
containing receptor 2 (DDR2), the fibroblast growth factor receptors FGFR1-3, TP53 
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and PIK3CA (2).  In small cell carcinoma inactivation of the tumour suppressor genes 
TP53 and Retinoblastoma 1 (RB1) are a pre-requisite in its development with further 
associations with MYC translocations described (4).   
 
As adenocarcinomas have seen the greatest advances in the application of therapy-
defining tumour profiling these tumours will be main focus of this article. The key 
molecular features of these tumours will be discussed with regards to their biological 
and therapeutic relevance. 
 
Key Molecular Targets 
EGFR 
EGFR is a transmembrane receptor tyrosine kinase (RTK) which, in the context of 
oncogenesis, is constitutively activated by a variety of somatic mutations.  These occur 
in the tyrosine kinase domain of the EGFR gene on chromosome 7 with the most 
frequent activating mutations being the exon 19 deletions (p.Glu746_Ala750), and 
exon 18 (p.Gly719Cys, p.Gly719Ser, p.Gly719Ala) and exon 21 (p.Leu858Arg also 
known as L858R) substitutions.  Subsequent activation of EGFR triggers several 
downstream signalling pathways including RAS, PI3K, and STAT3.  Together, they 
regulate gene transcription, cell differentiation, proliferation, migration and apoptosis.  
 
EGFR was the first of the molecular targets to be characterised as a therapeutic target 
in lung adenocarcinoma with the introduction of Gefitinib (EGFR-tyrosine kinase 
inhibitor (TKI)) which demonstrated the need to define somatic driver mutations in the 
context of molecular therapies.  Early trials of Gefitinib showed that the presence of 
an activating EGFR mutation significantly improved overall progression free survival 
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whilst treatment in patients without an EGFR mutation caused dramatically worse 
progression free survival (5). EGFR-TKIs are therefore superior to standard platinum-
based chemotherapies as first line treatment in this correct patient cohort with 
response rates ranging from 56-86%.  Importantly, not all EGFR mutations are 
amenable to therapy with exon 20 insertions failing to respond. Additionally, resistance 
can emerge following TKI treatment due to a pThr790Met (also known as T790M) 
mutation in exon 20 altering the ATP-binding affinity of the kinase and leading to 
reduced binding of first generation TKIs. Development of third line TKIs which 
selectively target T790M are currently entering clinical practice (3).  
 
ALK 
The ALK protein is a member of the insulin receptor subfamily of RTKs.  ALK gene 
rearrangements occur in <5% of adenocarcinomas and are often associated with 
young, non-smokers with clinically advanced disease.  Typically, rearrangements 
occur as a short inversion of the gene on chromosome 2p in which intron 10 fuses with 
the intron 13 of the upstream echinoderm microtubule associated protein-like 4 
(EML4).  Less frequently, ALK binds to kinesin family member 5B (KIF5B), TFG, and 
KLC-1. ALK-positive lung cancers are highly responsive to ATP-competitive kinase 
inhibition by ALK-TKI therapies which specifically target human ALK and human 
growth factor (HGF) receptors (6). Response rates are approximately 60% with a 
median progression-free survival of 8.1 months.  Crizotinib is therefore approved for 
first line and subsequent line treatments.  Drug resistance however typically develops 
after 11 months of treatment due to further alterations in ALK or activation of bypass 
signalling pathways including EGFR, KRAS and KIT.  Development and application of 
second line therapies including Ceritinib is therefore ongoing. 
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ROS-1 
The ROS1 gene (chromosome 6q) also encodes an RTK within the insulin receptor 
subfamily and shares many similarities to ALK.  Various gene rearrangements of this 
proto-oncogene can occur with fusion partners including CD74, SLC34A2/NaPi2b, 
and FIG all of which result in constitutive activation of the receptor.  Importantly, the 
nature of the ROS1-binding partner does not appear to be important in determining 
response to therapy (7).  Downstream signalling pathways are similar to other receptor 
tyrosine kinases with comparable effects on cellular function.   ROS1-associated 
fusions are present in approximately 2% of all adenocarcinomas and, as with ALK 
rearrangements, are more prevalent in young, non-smoking patients. Treatment of 
ROS1-positive tumours with Crizotinib results in a progression-free survival of 
19.2 months with a response rate of 72%.   
 
PD-L1  
Although not specific to NSCLC the role of programmed death 1 / programmed death 
ligand 1 (PD-1/PD-L1) as an immunotherapeutic target has highlighted the influence 
of the tumour microenvironment both on tumour development and as an avenue for 
therapeutic intervention.  Under physiological conditions immune checkpoint receptors 
such as PD1 and cytotoxic T-lymphocyte–associated protein 4 (CTLA4) are essential 
in the process of discriminating “self” from “non-self” antigens in the development of 
immune tolerance.  
 
Certain sub-types of solid tumours (including some lung adenocarcinoma, squamous 
cell carcinoma and small cell carcinoma) express PD-L1 on their cell surface.  Tumour 
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antigens are presented on major histocompatibility complexes (MHCs) which, upon 
binding to T cell receptors, allows T cell activation and generation of an appropriate 
immune response.  However, when PD-L1 is concurrently expressed on the tumour 
cell surface it binds to PD1 present on CD8+ T cells inhibiting T cell proliferation and 
clonal expansion thereby preventing identification of “non-self” antigens.  By inducing 
this state of immune tolerance tumour cells can evade immune surveillance and grow 
in a protected and permissive environment.  Anti-PD-L1 and anti-PD-1 monoclonal 
antibodies block the inhibitory interaction between PD-1 and PD-L1 allowing T-cell 
recognition of tumour cell antigens and generation of an appropriate immune response 
and subsequent tumour cell death. 
 
As the therapeutic target is tumour-associated immunity the use of PD-L1 inhibitors is 
not limited by specific tumour types or driver mutations but rather cell surface protein 
expression.  Both squamous cell carcinomas and adenocarcinomas that express PD-
L1 are therefore amenable to therapy with improved overall survival relative to 
conventional chemotherapy in NSCLC (8).  Ongoing studies are, at present, evaluating 
the potential efficacy in small cell carcinoma.   
 
Laboratory Aspects of Molecular Testing in NSCLC 
Molecular testing in lung cancer presents a number of process issues for diagnostic 
histology / cytology labs which have been reviewed elsewhere (9). Some are generic 
to molecular testing in general eg. optimisation of fixation and avoidance of cross 
contamination during processing and sectioning. In order to minimise this it is 
particularly important that block sectioning for DNA or RNA extraction are carried out 
in a ‘clean’ area of the laboratory designated for this purpose by appropriately trained 
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staff and not simply carried out at the same time as routine sections for histology and 
immunohistochemistry (IHC).  
 
In addition, there are issues more specific to testing in NSCLC. The vast majority of 
patients with NSCLC are diagnosed on small bronchoscopic biopsies, percutaneous 
biopsies or a variety of cytology specimens (bronchial cytology, sputum cytology, 
pleural aspiration or increasingly lymph node FNAs from the mediastinum and neck). 
These specimens often contain limited numbers of tumour cells. This requires 
attention as to how these specimens are handled in order to optimise the tissue 
available for both diagnosis and molecular testing. Strategies that can be employed 
include clipping up core biopsies individually in separate cassettes, cutting spares for 
IHC at the time of initial sectioning to reduce tissue loss as blocks are ‘faced-up’ on 
the microtome and the use of double immunohistochemical staining (eg CK7 + TTF1) 
to reduce the number of sections required.  Cytology specimens should be processed 
in a manner that allows the production of cell blocks which can then be used for IHC 
and molecular testing.  
 
Fixation with both formalin or alcohol based fixatives appears to be equally good for 
molecular testing for EGFR mutations as well as IHC / FISH (fluorescent in-situ 
hybridisation) detection of ALK/ROS1 translocations. PD-L1 testing by IHC is, 
however, currently only validated in formalin fixed biopsy specimens and therefore 
alcohol fixed cytology specimens may not be suitable for assessment; although this is 
very much an area in evolution. 
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The role of the pathologist 
While there has been considerable focus on molecular testing of NSCLC it is important 
to recognise that the pathologist’s primary responsibility is to make a diagnosis and 
secondly to determine, where possible, a cell type. It is however important that this is 
achieved in a manner that does not ‘waste’ tissue that may be required for molecular 
testing following the pathological diagnosis. When IHC is undertaken the antibodies 
used should be carefully selected and the indiscriminate use of broad panels should 
be avoided (10). 
 
In cases where molecular testing is required sections from the case (biopsies or cell 
blocks) need to be reviewed by the pathologist and the percentage of tumour cells 
present assessed. In biopsy specimens it is often possible to increase this by 
identifying areas that can be macroscopically dissected from the slide either by 
positively selecting an area of high tumour concentration or by removing fragments 
containing little or no tumour. The minimum percentage tumour cells required varies 
depending on the technology used and a decision on which cases are insufficient to 
test requires discussion with the molecular laboratory. 
 
Which specimens to test and when to test them 
Current guidance is that molecular testing for EGFR and ALK / ROS1 should be carried 
out on adenocarcinomas, NSCLC - not otherwise specified (NOS) and in cases of 
squamous carcinoma where there is any suspicion that the histology may not be 
entirely representative eg. squamous carcinomas in non-smokers or cases where 
there is co-incidental mucin noted on special stains (11). Initially studies suggested 
that EGFR mutations and ALK/ROS1 translocations were found in non-smoking 
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female patients but it is now recognised that they are encountered in males and current 
smokers albeit at a lower frequency. There is therefore no indication to select cases 
for testing on the basis of sex or smoking history. There is some data which suggests 
that in Caucasian patients the absence of expression of TTF1 by the tumour cells has 
a strong negative predictive value for activating EGFR mutations in adenocarcinomas 
although this is less clear for ALK/ROS1(12).. 
 
The issue of when to test is more contentious. Some centres have adopted a reflex 
testing model where the pathologist routinely requests testing in all appropriate cases 
at the time of diagnosis. This, it is argued, reduces the risk of missing cases that should 
be tested and expedites the availability of the result. Tyrosine kinase inhibitors for 
EGFR mutations and ALK/ROS1 translocations are, however, prescribed to patients 
with advanced stage disease. They are not indicated in patients with more limited 
disease who will be managed surgically or with radical chemotherapy/radiotherapy 
with ‘curative intent’. Similarly, there is no role for these drugs as post-operative 
adjuvant therapy. Reflex testing is therefore wasteful of resources. The alternative 
approach is a ‘request’ or ‘on-demand model’ when testing is only undertaken 
following discussion of the case with an oncologist where the presence or absence of 
a mutation will immediately direct management. This approach is more efficient in 
terms of resource use but has the potential to delay the availability of the result, 
particularly when cases need to be sent to another institution for testing. Individual 
centres need to agree a model which suits their clinical requirements but we have 
adopted a pragmatic approach where we reflexively test samples in patients where we 
know from the nature of the specimen (eg. liver biopsies, pleura aspirates) that the 
patient has advanced stage disease or the history accompanying the request states 
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this. As all other cases are discussed at the MDT, testing can be requested by the 
oncologist at that stage, or at a later date, when the presence of a mutation is relevant 
to the patient’s management. 
 
Assessment of PD-L1 testing is relevant to all subtypes of NSCLC. In the second line 
setting it can be performed at the time of relapse and there is evidence to suggest that 
assessment on a contemporaneous biopsy is better as expression levels can be 
altered by chemotherapy. First line therapy with PD-L1 inhibitors is again primarily 
indicated in patients with advanced disease and the approaches to patient selection 
for testing is similar to that used for EGFR and ALK/ROS1.  
 
Methodologies for Molecular Testing in NSCLC 
General considerations 
It is well known that solid tumour specimens contain a proportion of non-tumour cells, 
including immune and stromal cells, which do not carry the mutation of interest and 
dilute tumour DNA. Careful histological assessment of each specimen is required to 
estimate the proportion of tumour cells and determine if a sample is suitable for 
molecular analysis (11, 13). It has been recommended that mutation detection 
methods should have a minimum limit of detection (the minimum proportion of mutated 
DNA which must be present for reliable detection) of 10% mutated DNA; equivalent at 
least 20% tumour cells (13), although gene amplification or polysomy may permit the 
detection of mutations in less tumour-rich tissues. Accurate and reproducible 
assessment of tumour percentage in tissue sections is, however, difficult and subject 
to large inter-observer variation which may affect the validity of molecular testing 
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results (13). To address this UK NEQAS have launched a pilot EQA scheme 
(info@ukneqas-molgen.org.uk) for tissue assessment allowing individual assessors to 
benchmark their results against their peers. 
 
Lung cancer specimens are routinely formalin fixed and paraffin embedded (FFPE) 
and therefore yield poor quality and fragmented DNA; in addition, formalin treatment 
causes adducts to the DNA which can produce false positive mutations (14). 
Cytological preparations, which typically undergo primary fixation in alcohol, frequently 
yield better quality DNA although depending on the anatomical site of the specimen 
they may also contain a high proportion of non-neoplastic cells. 
 
EGFR 
Any somatic EGFR mutation detection method should be able to detect all clinically 
relevant mutations present in greater than 1% of the target population (13) although 
accurate estimates of mutation incidence can be difficult to attain and are biased by 
the method chosen in the reference cohort. Although antibodies have been developed 
for the detection of mutated EGFR protein by IHC they are only designed to bind to 
the two most common mutations. This means that their overall analytical sensitivity is 
not sufficient for routine clinical use (15). Currently, nucleic acid based techniques offer 
the only realistic methods for EGFR mutation detection in NSCLC (13). Clinically 
relevant EGFR mutations are concentrated in exons 18, 19, 20 and 21 and Sanger 
sequencing of these exons is achievable in most lung tissues. However successful 
mutation detection by Sanger sequencing requires at least 20% of the DNA to be 
mutated, equivalent to a sample with at least 40% tumour cells. For many lung cancer 
samples (over 50% in our experience) this is not achievable without laser capture 
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microdissection; something which is not routinely available in clinical laboratories. 
Techniques with a lower limit of detection which are more appropriate for lung 
specimens include allele specific PCR, fragment analysis of PCR products (for small 
insertions and deletions) and more sensitive sequencing technologies such as 
pyrosequencing and next generation sequencing (NGS). There are also several 
commercially available kits for the detection of somatic EGFR mutations including the 
COBAS® EGFR mutation test (Roche Diagnostics), the therascreen® EGFR RGQ 
PCR and EGFR Pyro kits (Qiagen) and the PNAClamp™ EGFR Mutation Detection 
kit (Panagene). Such kits, with CE IVD status (indicating compliance with European 
Union directives and standards for in-vitro diagnostics), only require verification rather 
than a full validation and represent a rapid way for laboratories to implement EGFR 
analysis. Molecular pathology techniques for the analysis of NSCLC have been 
reviewed in more detail elsewhere (16).  
ALK  
Initial clinical trials investigating ALK inhibitors for the treatment of lung cancer relied 
on FISH with break-apart probes to detect re-arrangements in the ALK gene (17). 
However the implementation of this costly analysis into routine clinical use has proved 
challenging due to the large patient population and very low incidence of the ALK re-
arrangement. More recently the development of IHC assays, designed to detect 
increased expression of the ALK protein caused by re-arrangement of the ALK gene, 
has allowed for rapid and low cost screening prior to the confirmation of positive results 
by FISH (figure 1). This has proved controversial, with some groups claiming to find 
IHC negative FISH positive cases. Despite this several antibodies are now available 
[5A4 (Novocastra) and D5F3 (Ventana)] which are generally accepted to show robust 
performance in combination with FISH or as a stand-alone test in unequivocal cases 
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(18). The significance of IHC-positive, FISH-negative cases remain unclear but there 
is some evidence to suggest that these cases may respond to ALK targeted TKI 
therapy and as such these should be reported. 
 
Some laboratories have developed multiplexed reverse transcription PCR (RT-PCR) 
assays for the detection of ALK gene re-arrangements. These methods use PCR 
primers that have been designed to flank potential breakpoints in mRNA derived from 
tumour tissues (19); however, large numbers of primers would be required to detect 
all possible ALK fusion partners. NGS has also been applied to the detection of ALK, 
and other, gene re-arrangements in lung cancer with some success (20) but the 
reliance of these assays on RNA isolated from FFPE tissues may, however, restrict 
their use in poorer quality samples.  
ROS1 
The detection of rearrangements in the ROS1 gene is in the process of entering routine 
testing in the UK and is widely performed elsewhere. Similarly to ALK, trials showing 
benefit from crizotinib in patients with ROS1 rearranged lung cancer have depended 
on analysis of the gene using break-apart FISH (21). Given the rarity of the ROS1 
rearrangement it is hoped that a similar IHC/FISH algorithm will prove to be effective 
in detecting this additional group of patients. Commercially available NGS panels to 
detect fusion genes in lung cancer have been designed to include ROS1 
rearrangements. 
KRAS 
Although clinical analyses are commonly restricted to biomarkers with direct 
therapeutic application, other molecular characteristics may show utility. KRAS 
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mutations are common in NSCLC and are widely accepted to be mutually exclusive 
with EGFR mutations and ALK translocations. In addition they have been shown to 
have a strong negative predictive value for response to EGFR TKIs (22). Considering 
the low incidence of EGFR or ALK aberrations in Caucasian NSCLC patients the 
detection of a KRAS mutation can reduce the number of ‘insufficient’ reports for the 
large number of samples with sub-optimal neoplastic cell content and may prevent the 
need for some repeat biopsies. Depending on the detection method selected KRAS 
mutation analysis could be rapid, low cost and fit easily into a routine testing algorithm. 
 
PD-L1 
Assessment of PD-L1 expression by NSCLC is carried out by IHC (figure 2). This is 
however a very complex field with different drugs developed by different 
pharmaceutical companies having specific testing kits with different primary antibodies 
and different scoring criteria (23). The situation has been further complicated by 
licensing authorities in the USA and Europe requiring tumour testing by IHC for some 
PD-L1 inhibitors but not others. Assessment of expression, when required, should be 
carried out on FFPE tissues. Alcohol fixation is believed to affect the level of staining 
and the use of these assays on cytology specimens has not been validated. 
Expression of PDL1 is highly variable and needs to be carried out according to the 
criteria set out for each of the different IHC primary antibodies / kits. Care needs to be 
taken not to over interpret non-specific staining of degenerate tumour cells, ‘edge 
effect’ staining in free lying cells and apparent staining due to expression on the 
surface of admixed macrophages.  Reports must state the primary antibody / kit used 
and the percentage of tumour cells expressing PD-L1.   
 
17 
 
Clinical Reporting of Results  
It is now widely accepted and recommended as good practice to report molecular 
pathology test results in an integrated way (9).  This approach ensures clinicians 
receive a timely and accurate report on which clinical management decisions can be 
made.  The molecular pathology report should be short and concise but at the same 
time it must contain important details such as: patient’s demographics, sample details 
and the reason for testing. In addition the report should detail all the technical 
information required to correctly interpret the result and there should be an 
unambiguous clinical statement to guide therapeutic decision making. This should 
describe what the result means for the patient and the class of drugs the patient may 
or may not be suitable for (Table 1).  
 
Future Developments 
Next generation sequencing (NGS) 
NGS is an attractive platform that offers high sensitivity testing at a relatively low cost. 
As NGS platforms evolve they require a small amount of DNA, compared to performing 
multiple single gene tests, and provide results for multiple oncogenic targets of 
interest. However, in order to maintain low costs, batching would be advisable and this 
could potentially impact on turn-around times. The addition of fusion panels to NGS 
technology to detect ALK or ROS1 rearrangements makes it even more attractive and 
reduces both costs and hands-on technical time required for FISH (24). A recent report 
from USA has however highlighted the issue of potential poor reproducibility that may 
be encountered using NGS panels (25).  
 
Circulating tumour DNA 
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Patients with advanced NSCLC with an EGFR mutation are likely to respond well to 
TKI therapy and benefit from an improved quality of life, but for the majority TKI 
resistance and disease progression occurs. In 50-60% of patients this has been 
associated with the overgrowth of tumour cell clones harbouring an additional EGFR 
T790M mutation. These patients can now be treated with new third generation TKIs, 
such as osimertinib which specifically targets the T790M mutation in tumours. The 
need for repeat tissue sampling to detect this mutation has, however, been seen as a 
limiting factor. In recent years a number of studies have demonstrated the potential 
for using circulating cell-free DNA (cfDNA) as a non-invasive ‘liquid biopsy’ for the 
analysis of actionable mutations in a number of cancer types; including advanced 
NSCLC. The use of cfDNA to detect the presence of a T790M mutation in patients 
treated with EGFR TKIs is now the test of choice to identify patients eligible for third 
generation TKIs such as osimertinib (26). It is important, however, to also test the 
sample for the initial known mutation as well as the T790M as this provides an internal 
positive control for the presence of tumour DNA. In cases where the initial mutation is 
not detected the sample may contain insufficient tumour DNA and these patients 
should be considered for repeat tissue biopsy and traditional tissue based testing if 
this is clinically indicated. In addition EGFR cfDNA analysis has the potential to be 
used for therapy stratification if a tumour sample is not evaluable for primary testing.  
 
Other biomarkers  
In addition to EGFR, ALK, ROS1 and KRAS several other potential therapeutic targets 
have been identified such as BRAF, PIK3CA, c-MET, HER2, RET, DDR2, FGFR. 
These targets are already linked to active agents approved for other indications or 
tumour types and diagnostic test are already in use. Of these, DDR2 and FGFR are 
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directed at squamous cell carcinoma, a tumour type not currently tested in the 
molecular laboratories due to the lack of therapeutic targets available. It is likely over 
the coming years that therapeutic agents against some, or all, of these targets (and 
others) will enter clinical practice resulting in the need for a more extended panel of 
testing on a routine basis in all forms of lung cancer. While the use of NGS panels will 
help to deliver this the availability of sufficient good quality tumour tissue for testing 
may remain an issue. 
 
Conclusion 
The prognosis for patients with advanced stage lung cancer is poor. While the 
application of molecular technologies and an understanding of immunotherapy 
provides potential new therapeutic options we need to recognise that only a small 
proportion of patients will have tumours suitable for these agents and that they remain 
palliative in nature. As we identify new mutations and targets the proportion of patients 
who may benefit from ‘personalised medicine’ will hopefully increase. Developments 
in this area present new challenges for pathology departments, in the way laboratories 
are organised, as well as pathologists who must now think beyond the ‘diagnosis’. 
Lung cancer reports must now integrate the traditional morphological aspects of 
pathology with molecular features which will guide clinical decision making placing the 
pathologist at the centre of lung cancer patient management.   
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Figure 1. 
Pulmonary adenocarcinoma with a non-mucinous lepidic and papillary pattern (A). 
Molecular testing showed wild type KRAS and EGFR. Immunohistochemistry for ALK 
protein using the D5F3 monoclonal antibody shows strong cytoplasmic staining with a 
rather granular appearance (B). FISH performed using Vysis break apart probes 
demonstrates splitting of the red and green markers (white arrows) in keeping with 
ALK rearrangement.  
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Figure 2 
Immunohistochemistry for PD-L1 using the Dako 22C3 pharmaDx kit. (A&B) Areas of 
an adenocarcinoma which showed high levels of expression but with different 
intensity. The overall expression of this tumour was assessed at around 80%. (C&D) 
Sections from a poorly differentiated squamous carcinoma which showed only very 
focal PD-L1 expression (C) which was weak and only present in a few cells. The 
majority of the tumour cells were negative (D) and overall expression was assessed 
as <1%. 
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Table 1 
 
Summary of molecular targets which are currently routinely available in non-
small cell lung cancer 
 
Target Tumour type Mutation(s) Method(s) 
Examples of drug(s) 
that may be indicated$ 
EGFR 
Non-
squamous, 
NSCLC 
Exon 18 mutations PCR 
gefitinib, erlotinib, 
afatinib Exon 19 deletions
# PCR 
Exon 21 eg L858R PCR 
Exon 20 eg T790M* PCR osimertinib 
ALK 
Non-
squamous, 
NSCLC 
Translocation IHC, FISH, RT-PCR crizotinib, seritinib 
ROS1 
Non-
squamous, 
NSCLC 
Translocation IHC, FISH, RT-PCR crizotinib 
PDL-1 expression All NSCLC None IHC nivolumab, pembrolizumab 
KRAS  Point mutations codons 12, 13, 61 PCR None available 
PCR – polymerase chain reaction, RT-PCR – reverse transcriptase polymerase chain reaction, 
IHC – immunohistochemistry, FISH – fluorescent in-situ hybridisation 
$ This list of drugs is provided for illustrative purposes and is not exhaustive. For further 
information referral should be made to appropriate local formularies. 
# afatinib may be preferred to other TKIs in patients with exon 19 deletions 
* mutation associated with resistance to first and second line tyrosine kinase inhibitors 
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Practice Points 
1. Molecular testing of advanced stage non-small cell lung carcinoma, especially 
adenocarcinoma,  is now standard practice. 
2. Pathologists have a critical role in ensuring small diagnostic specimens are 
carefully handled to ensure that sufficient good quality material is available, 
where ever possible, for testing after the traditional diagnostic process is 
completed. 
3. Testing uses a variety of methodologies including PCR, FISH and IHC to 
detect specific genetic alterations, translocations and protein expression in 
tumour cells to predict response to specific classes of drugs. 
4. Currently only a minority of patients have tumours with specific features that 
allow use of these new drugs but this is likely to change and the range of tests 
that require to be carried out will expand. 
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